DDInter740 DDInter448
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is regulated by {v} (Gene) LYN
LYN {u} (Gene) is bound by {v} (Compound) Crizotinib
Flecainide {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) interacts with {v} (Gene) MAP3K3
MAP3K3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Crizotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Interstitial lung disease
Interstitial lung disease {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Crizotinib (Compound)
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Crizotinib (Compound)
Flecainide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Crizotinib
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is regulated by LYN (Gene) and LYN (Gene) is bound by Crizotinib (Compound)
Flecainide (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) interacts with MAP3K3 (Gene) and MAP3K3 (Gene) is bound by Crizotinib (Compound)
Flecainide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Flecainide (Compound) causes Interstitial lung disease (Side Effect) and Interstitial lung disease (Side Effect) is caused by Gefitinib (Compound) and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Crizotinib
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)